Interesting studies evaluated a novel radiolabeled GRPR antagonist, NeoBOMB1, radiolabeled with [67/68Ga/111In/177Lu] as a theranostic tool in a prostate cancer animal model [132] and in prostate cancer patients [133]. Here, GRPR is linked to prostate cancer.